Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.
HealthDay on MSN17h
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate CancerFor patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...
Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback